Circulating Proteasome Level Is an Independent Prognostic Factor for Survival in Patients with Multiple Myeloma

The proteasome is a nonlysosomal proteolytic complex which is essentially involved in intracellular degradation of ubiquitinated proteins. This process includes the turnover of proteins which are involved in cell cycle regulation and apoptosis. A constitutively increased proteasome activity has been...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2004-11, Vol.104 (11), p.1486-1486
Main Authors: Jakob, Christian, Egerer, Karl, Feist, Eugen, Zavrski, Ivana, Eucker, Jan, Heider, Ulrike, Burmester, Gerd, Possinger, Kurt, Kloetzel, Peter M., Sezer, Orhan
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The proteasome is a nonlysosomal proteolytic complex which is essentially involved in intracellular degradation of ubiquitinated proteins. This process includes the turnover of proteins which are involved in cell cycle regulation and apoptosis. A constitutively increased proteasome activity has been found in multiple myeloma. Treatment with the proteasome inhibitor bortezomib resulted in induction of remission in a substantial portion of patients with relapsed or refractory multiple myeloma. The objective of the present study was to investigate the clinical significance of circulating levels of the 20S proteasome in patients with monoclonal gammopathy of undetermined significance (MGUS) or multiple myeloma (MM). To detect proteasome concentrations in peripheral blood samples, we developed a sandwich enzyme-linked immunosorbent assay (ELISA) using anti-20S proteasome antibodies. Serum proteasome levels were measured in 200 individuals, 85 normal donors and 115 patients with MGUS or multiple myeloma. Patients with multiple myeloma had significantly (P
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.V104.11.1486.1486